Submit a Release
Home
All
ESG
Health
Technology
Finance
Contributors
Sub Menu
Submit a Release
main-search-pop
Main menu
Oncoinvent ASA: Second half 2025 results
Contributed by:
PR Newswire
Tags
ONCOINVENT-Conf-Call
More Like This
Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer
Oncoinvent ASA: Invitation to Result Presentation Q4 2024
Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update
Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression
Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients
Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Treat Ovarian Cancer
Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases
BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue
